Want to come work in clinical development as a statistics leader in for next generation respiratory assets. Looking for an ambitious and motivated individual to join my team. Despite the job location being US, UK/Remote also considered! https://t.co/y8dRbH4BM2

Our cohort study assessing the severity of #CVD in people with #CHD using indicators recorded in #primarycare vs. hospital admission & mortality outcomes @Open_HeartBMJ #openaccess @UoMOpenAccess https://t.co/dde0nrdfzY

Our new #openaccess paper on the severity of #CVD in adults with #CHD in England w @CPRD #PrimaryCare & linked data. @dataevan @mmamas1973 @RutterMK @VanMarwijkHarm @prof_tweet @CizCG @StephenFWeng @profbuchan @NielsPeek et al. @PrimaryCareMcr @NIHRSPCR https://t.co/dde0nrdfzY

Read our latest #research published with @SpringerNature in @BMC_series, on the BMI trajectory of overweight and obese individuals in the general population, and the risk of cardiovascular disease, heart failure and death. @rkakyea @StephenFWeng https://t.co/8fGNaHz5hK

Our recently published work on Gender differences in CVD morbidity associated with FH, featured in a US-based healthcare professional website, MedPage today https://t.co/DDUL8rlNxl

@NIHRSPCR-funded PhD study assessing incidence of first-ever stroke and subsequent major adverse outcomes with @StephenFWeng @dataevan @fwasselbergs @DrRiyazPatel @GeorgeNtaios @YanaVinogradov5 Prof Nadeem Qureshi & Prof Joe Kai

Our recent paper published in Atherosclerosis, shows that the higher cardiovascular disease risk due to familial hypercholesterolaemia, is higher in women than in men. Available online at https://t.co/1Qgup3KApo. @ATHjournal, Prof Nadeem Qureshi, Prof Joe Kai, @StephenFWeng

Our latest @NIHRSPCR-funded research on detecting FH in primary care has been published with npj Digital Medicine. Read here: https://t.co/gUrN0r2tjG @StephenFWeng, Prof. Nadeem Qureshi, Prof. Joe Kai #npjdigitalmed

Want to work on adaptive trials, phase 0-4, vaccines, new therapies in CVD, oncology and statistical methods. We're expanding in Statistical Decision Sciences. Flex working, great pay, benefits! Get in touch, happy to chat. https://t.co/ZLj7Cmz1P5 https://t.co/ikzjgwSieR

https://t.co/Bu6ost4Cg2 Very interesting article

For R users out there - R markdown will change your life

Congratulations @Salwasz278 @dataevan @CizCG @prof_tweet @StephenFWeng and all authors!

Wondering why so many people are talking about treating #COVID19 with #Zinc? Is this evidence based? Find out in the rapid review pre-print by myself and @rkakyea: https://t.co/FLxcIOLptF @OxPrimaryCare @WellcomeOpenRes

Today marks my last day at the University of Nottingham. It has been a tremendous experience to study, learn and work here, with great support of colleagues through the years. Grateful for the next opportunity with Janssen J&J as Principal with Statistical Decision Sciences!

New *non-COVID19* paper: our @NIHRSPCR-funded work assessing disease severity in 139,626 people with #T2D vs. hospitalisation & mortality outcomes #diabetes #bigdata #openaccess @dataevan @mmamas1973 @RutterMK @PrimaryCareMcr @FBMH_UoM @UoMOpenAccess https://t.co/cpSyGvuSV6

Between 15 Jan - 3 March, seven updates to case definitions.

https://t.co/t46Tjy3Ld7 This study is so interesting. Shifts in case definitions over time. Many SEIR models in early phases have relied infection dynamics parameters from Wuhan. Modelling is the art of quantifying uncertainty. Needs careful interpretation

(3) Which patients are at risk of developing a pulmonary embolism?  (4) Which Covid-19 patients are at higher risk of cardiovascular secondary events?

(2) Can we predict which Covid-19 patients will have acute cardiac complications including viral myocarditis, type 1 and 2 myocardial infarctions, heart failure, acute coronary syndromes, and arrhythmias?

Key questions to be answered: (1) What is the role of hypertension in the outcome of Covid-19: is it causative? Can secondary tissue microvascular lesions be characterized and explained?